Reports Q1 revenue $19.37M, consensus $17.87M. “We had a strong start to fiscal 2026, with our sustained commercial momentum generating revenue growth of over 50% in the first quarter,” said Brian Webster, president and CEO. “We also continued to make progress on several key operational objectives, including growing the commercial organization, enhancing our revenue cycle management capabilities, and expanding gross margin. As we progress on our journey to category leadership, we remain focused on both market share capture and growing the wearable defibrillator market, while executing on our commitments to patients and their prescribers.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- KMTS Earnings this Week: How Will it Perform?
- Kestra Medical’s 2025 Annual Shareholder Meeting Outcomes
- RxSight appoints Raymond Cohen to its board of directors
- Kestra Medical Technologies Ltd.: Balanced Hold Rating Amid Revenue Growth and EBITDA Challenges
- Kestra Medical Technologies Reports Strong Revenue Growth